

Table S1: Baseline demographic and clinical characteristics by vital status at 3-month follow-up.

Three-month vital status			
Variable	Alive N=751	Dead N=161	p-value
Patient characteristics			
Male sex, N (%)	465 (61.9)	96 (59.6)	0.59
Age, year	54.4 ± 13.2	67.5 ± 10.1	<0.001
BMI, kg/m²	27.0 ± 4.9	27.4 ± 5.5	0.42
Race, N (%)			0.89
White/Caucasian	615 (85.2)	131 (85.6)	
Non-White	107 (14.8)	22 (14.4)	
Tobacco use, N (%)			0.06
Current	33 (4.4)	4 (2.5)	
Prior	154 (20.5)	47 (29.2)	
Never	377 (50.2)	79 (49.1)	
Unknown	187 (24.9)	31 (19.2)	
Clinical frailty scale, AU	2.7 ± 1.3	3.9 ± 1.7	<0.001
Comorbidities, N (%)			
Obesity	140 (23.1)	40 (28.4)	0.19
Hypertension	613 (81.6)	132 (82.0)	0.91
Diabetes Mellitus	206 (27.4)	74 (46.0)	<0.001
Coronary artery disease	103 (13.7)	49 (30.4)	<0.001
Heart failure	40 (5.3)	39 (24.2)	<0.001
Chronic lung disease	49 (6.5)	20 (12.4)	0.01
Active malignancy	23 (3.1)	15 (9.3)	<0.001
Auto-immune disease	43 (5.7)	6 (3.7)	0.31
Primary kidney disease, N (%)			
Primary Glomerulonephritis	133 (18.1)	27 (17.0)	0.73
Pyelonephritis	20 (2.7)	6 (3.8)	0.48
Interstitial nephritis	26 (3.5)	6 (3.8)	0.89
Hereditary kidney disease	97 (13.2)	21 (13.2)	0.99
Congenital diseases	38 (5.2)	2 (1.3)	0.03
Vascular diseases	51 (6.9)	21 (13.2)	0.009
Sec. glomerular disease	33 (4.5)	7 (4.4)	0.96
Diabetic kidney disease	69 (9.4)	29 (18.2)	0.001
Other	158 (21.5)	26 (16.3)	0.14
Unknown	109 (14.8)	14 (8.8)	0.045
Time since transplantation, N (%)			
<1 year	64 (8.6)	17 (10.7)	
1-5 years	298 (40.0)	48 (30.2)	
>5 years	382 (51.3)	94 (59.1)	
Medication use, N (%)			
Use of RAAS inhibition	309 (41.5)	59 (36.6)	0.26
Use of immunosuppressive medication			
Triple therapy	468 (63.3)	107 (66.9)	0.68
Tacrolimus + Prednisone + Mycophenolate	414 (88.5)	94 (87.8)	0.86

Others	54 (11.5)	13 (12.1)	
Dual therapy	253 (34.2)	49 (30.6)	
CNI + Prednisone	102 (40.3)	23 (46.9)	0.79
CNI + Antimetabolite	98 (38.7)	16 (32.6)	
Prednisone + Antimetabolite	33 (13.0)	7 (14.3)	
Others	20 (7.9)	3 (6.1)	
Disease related characteristics			
Presenting symptoms, N (%)			
Sore throat	129 (18.7)	18 (11.8)	0.04
Cough	438 (60.7)	105 (67.7)	0.10
Shortness of breath	252 (35.0)	101 (63.9)	<0.001
Fever	497 (68.3)	117 (75.5)	0.08
Headache	149 (22.0)	22 (15.3)	0.07
Nausea or vomiting	106 (15.3)	27 (18.1)	0.38
Diarrhea	197 (28.1)	36 (24.0)	0.31
Myalgia or arthralgia	222 (32.6)	44 (30.3)	0.60
Vital signs			
Temperature, °C	37.6 ± 1.1	37.5 ± 1.0	0.20
Respiration rate, /min	19.9 ± 6.4	24.0 ± 7.7	<0.001
O2 saturation room air, %	94.6 ± 6.6	91.2 ± 8.4	<0.001
Systolic BP, mmHg	131.5 ± 19.3	136.6 ± 26.2	0.01
Diastolic BP, mmHg	78.8 ± 14.1	75.2 ± 14.3	0.01
Pulse rate, BPM	87.5 ± 16.4	86.7 ± 19.3	0.63
Laboratory test results			
eGFR CKD EPI, ml/min/1.73m ²	40 (26, 59)	26 (18, 36)	<0.001
Creatinine increase (>25%)	160 (21.3)	70 (43.5)	<0.001
Lymphocytes, x1000/μL	0.9 (0.6, 1.5)	0.7 (0.4, 0.9)	<0.001
CRP, mg/L	33 (7, 84)	73 (24, 140)	<0.001

Continuous variables are reported as mean ± SD or median (IQR). Groups were compared using one way ANOVA, Kruskal Wallis test or Chi-square test as appropriate. Obesity is defined as BMI >30 kg/m². *Abbreviations are:* BMI, body mass index; RAAS=Renin-angiotensin-aldosterone system; CNI= Calcineurin inhibitor; °C, degree Celsius; CRP, C-reactive protein; BP, blood pressure; O2, oxygen; eGFR, estimated glomerular filtration rate.

Table S2: Predictors for 3 month patient survival.

N=912 Variable	Multivariable analysis	
	Hazard ratio (95% confidence interval)	p-value
Patient characteristics		
Age groups		
• <40 years	Ref.	
• 40-49 years	1.77 (0.35, 8.83)	0.49
• 50-59 years	3.68 (0.87, 15.64)	0.08
• 60-69 years	4.94 (1.17, 20.85)	0.03
• ≥70 years	13.23 (3.15, 55.59)	<0.001
Clinical frailty scale, U	1.21 (1.09, 1.35)	0.001
Heart failure	1.94 (1.32, 2.85)	0.001
Diabetic kidney disease	1.46 (0.97, 2.21)	0.07
Shortness of breath	1.47 (1.02, 2.11)	0.036
Respiration rate, /min	1.04 (1.02, 1.07)	<0.001
Log(Lymphocytes), x1000/ μ L	0.69 (0.58, 0.83)	<0.001
Log(C-reactive Protein), mg/L	1.16 (1.02, 1.32)	0.025

Table S3: Association of number of immunosuppressive drugs with 3-month survival (Presented are hazard ratio with 95% Confidence Interval).

N=877	Triple therapy N=575	Dual therapy N=302
Event (event rate^a)	107 (2.1)	49 (1.9)
• Model 1	Ref.	0.88 (0.62, 1.24)
• Model 2	Ref.	0.71 (0.51, 1.00)
• Model 3	Ref.	0.78 (0.47, 1.12)
• Model 4	Ref.	0.73 (0.51, 1.05)

^aper 100 person weeks.

Model 1= Crude.

Model 2= Model 1 + age, sex, frailty.

Model 3= Model 2 + obesity, hypertension, diabetes, heart failure, chronic lung disease.

Model 4= Model 3 + eGFR, transplant duration.

Table S4: Association of type of immunosuppressive drug regimen with 3-month survival (Presented are hazard ratio with 95% Confidence Interval).

N=279	CNI + Prednisone N=125	CNI + Antimetabolite N=114	Prednisone + Antimetabolite N=40
Events (event rate^a)	23 (2.3)	16 (1.6)	7 (2.0)
• Model 1	Ref.	0.73 (0.38, 1.38)	0.92 (0.39, 2.14)
• Model 2	Ref.	1.13 (0.58, 2.19)	0.95 (0.40, 2.24)
• Model 3	Ref.	1.28 (0.61, 2.69)	1.06 (0.44, 2.53)
• Model 4	Ref.	1.24 (0.56, 2.74)	0.95 (0.38, 2.36)

CNI = tacrolimus or cyclosporine; Antimetabolite = azathioprine, Mycophenolate.

^aper 100 person weeks.

Model 1= Crude.

Model 2= Model 1 + age, sex, frailty.

Model 3= Model 2 + obesity, hypertension, diabetes, heart failure, chronic lung disease.

Model 4= Model 3 + estimated glomerular filtration rate, transplant duration.

Table S5: Baseline demographic and clinical characteristics by availability of graft function outcome data at 3-month follow-up.

Variable	Patients with complete data (N=487)	Patients with missing data (N=93)	Standardized difference
Patient characteristics			
Male sex, N (%)	302 (62.0)	59 (63.4)	0.030
Age, year	53.9 ± 13.7	54.6 ± 11.9	-0.054
BMI, kg/m ²	26.7 ± 4.5	27.2 ± 6.0	-0.097
Race, N (%)			0.138
White/Caucasian	386 (82.1)	62 (76.5)	
Non-White	84 (17.9)	19 (23.5)	
Tobacco use, N (%)			0.322
Current	22 (4.5)	7 (7.5)	
Prior	100 (20.5)	26 (28.0)	
Never	229 (47.0)	45 (48.4)	
Unknown	136 (27.9)	15 (16.1)	
Clinical frailty scale, AU	2.6 ± 1.3	2.8 ± 1.4	-0.147
Comorbidities, N (%)			
Obesity	85 (20.7)	21 (26.6)	-0.137
Hypertension	408 (83.8)	70 (75.3)	0.211
Diabetes Mellitus	136 (27.9)	24 (25.8)	0.048
Coronary artery disease	59 (12.1)	15 (16.1)	-0.115
Heart failure	25 (5.1)	5 (5.4)	-0.011
Chronic lung disease	29 (5.9)	9 (9.7)	-0.138
Active malignancy	16 (3.3)	2 (2.1)	0.070
Autoimmune disease	25 (5.1)	5 (5.4)	-0.011
Primary kidney disease, N (%)			
Primary Glomerulonephritis	102 (21.6)	15 (16.5)	0.129
Pyelonephritis	17 (3.6)	2 (2.2)	0.083
Interstitial nephritis	19 (4.0)	4 (4.4)	-0.019
Hereditary kidney disease	76 (16.1)	15 (16.5)	-0.011
Congenital diseases	25 (5.3)	12 (13.2)	-0.274
Vascular diseases	40 (8.5)	9 (9.9)	-0.049
Sec. glomerular disease	24 (5.1)	5 (5.5)	-0.019
Diabetic kidney disease	49 (10.4)	13 (14.3)	-0.119
Other	38 (8.0)	3 (3.3)	0.205
Unknown	83 (17.6)	13 (14.3)	0.089
Time since transplantation, N (%)			0.247
<1 year	36 (7.5)	14 (15.0)	
1-5 years	198 (41.2)	33 (35.5)	
>5 years	247 (51.3)	46 (49.5)	
Medication use, N (%)			
Use of RAAS inhibition	207 (42.9)	29 (31.5)	0.238
Use of immunosuppressive medication			0.231
Triple therapy	312 (65.4)	52 (56.5)	
Dual therapy	153 (33.1)	39 (42.4)	

Monotherapy	12 (2.5)	1 (1.1)	
Disease related characteristics			
Hospitalization, N (%)	344 (70.6)	47 (50.5)	0.420
ICU admission, N (%)	47 (13.7)	8 (17.0)	0.093
Presenting symptoms, N (%)			
Sore throat	93 (20.8)	18 (20.4)	0.078
Cough	286 (61.1)	53 (58.9)	0.045
Shortness of breath	172 (36.9)	35 (39.3)	0.050
Fever	311 (66.0)	53 (58.9)	0.148
Headache	95 (21.4)	19 (22.6)	0.040
Nausea or vomiting	70 (15.5)	8 (9.1)	0.195
Diarrhea	133 (29.3)	15 (17.0)	0.286
Myalgia or arthralgia	154 (34.6)	22 (25.6)	0.196
Vital signs			
Temperature, °C	37.6 ± 1.1	37.7 ± 0.9	-0.086
Respiration rate, /min	19.1 ± 5.8	21.0 ± 6.9	-0.271
O2 saturation room air, %	95.0 ± 5.1	95.9 ± 3.2	-0.213
Systolic BP, mmHg	131.5 ± 19.6	132.2 ± 17.5	-0.038
Diastolic BP, mmHg	79.1 ± 14.3	80.0 ± 12.6	-0.070
Pulse rate, BPM	87.5 ± 16.8	89.0 ± 13.9	-0.096
Laboratory test results			
eGFR CKD EPI, ml/min/1.73m ²	40 (26, 59)	38 (28, 61)	-0.022
Creatinine increase (>25%)	106 (21.8)	17 (18.3)	0.138
Lymphocytes, x1000/μL	0.9 (0.6, 1.4)	0.9 (0.5, 2.1)	-0.132
CRP, mg/L	29 (7, 71)	30 (5, 84)	-0.080

Continuous variables are reported as mean ± SD or median (IQR). Groups were compared using one way ANOVA, Kruskal Wallis test or Chi-square test as appropriate. Obesity is defined as BMI >30 kg/m². *Abbreviations are:* BMI, body mass index; RAAS=Renin-angiotensin-aldosterone system; CNI= Calcineurin inhibitor; °C, degree Celsius; CRP, C-reactive protein; BP, blood pressure; O2, oxygen; eGFR, estimated glomerular filtration rate.

Table S6: Baseline demographic and clinical characteristics by availability of functional and mental health outcome data at 3-months follow-up.

Variable	Patients with complete data (N=450)	Patients with missing data (N=130)	Standardized difference
Patient characteristics			
Male sex, N (%)	279 (62.0)	82 (63.1)	0.022
Age, year	53.7 ± 13.5	55.3 ± 13.1	-0.127
BMI, kg/m ²	26.7 ± 4.6	27.1 ± 5.4	-0.081
Race, N (%)			0.162
White/Caucasian	362 (82.6)	86 (76.1)	
Non-White	76 (17.3)	27 (23.9)	
Tobacco use, N (%)			0.191
Current	20 (4.4)	9 (6.9)	
Prior	94 (20.9)	32 (24.6)	
Never	212 (47.1)	62 (47.7)	
Unknown	124 (27.6)	27 (20.8)	
Clinical frailty scale, AU	2.6 ± 1.2	2.9 ± 1.6	-0.210
Comorbidities, N (%)			
Obesity	81 (21.5)	25 (22.1)	-0.014
Hypertension	376 (83.6)	102 (78.5)	0.130
Diabetes Mellitus	126 (28.0)	34 (26.1)	0.041
Coronary artery disease	52 (11.6)	22 (16.9)	-0.154
Heart failure	21 (4.7)	9 (6.9)	-0.096
Chronic lung disease	28 (6.2)	10 (7.7)	-0.058
Active malignancy	15 (3.3)	3 (2.3)	0.062
Autoimmune disease	23 (5.1)	7 (5.4)	-0.012
Primary kidney disease, N (%)			
Primary Glomerulonephritis	96 (22.0)	21 (16.5)	0.138
Pyelonephritis	14 (3.2)	5 (3.9)	-0.039
Interstitial nephritis	18 (4.1)	5 (3.9)	0.009
Hereditary kidney disease	74 (16.9)	17 (13.4)	0.099
Congenital diseases	25 (5.7)	12 (9.4)	-0.141
Vascular diseases	36 (8.2)	13 (10.2)	-0.069
Sec. glomerular disease	23 (5.3)	6 (4.7)	0.025
Diabetic kidney disease	43 (9.8)	19 (15.0)	-0.155
Other	33 (7.6)	8 (6.3)	0.049
Unknown	75 (17.2)	21 (16.5)	0.017
Time since transplantation, N (%)			0.124
<1 year	35 (7.9)	15 (11.5)	
1-5 years	157 (35.4)	46 (35.4)	
>5 years	252 (56.8)	69 (53.1)	
Medication use, N (%)			
Use of RAAS inhibition	190 (42.7)	46 (35.7)	0.145
Use of immunosuppressive medication			0.097
Triple therapy	286 (64.8)	78 (60.9)	
Dual therapy	146 (33.1)	46 (35.9)	

Monotherapy	9 (2.0)	4 (3.1)	
Disease related characteristics			
Hospitalization, N (%)	310 (68.9)	81 (62.3)	0.139
ICU admission, N (%)	40 (12.9)	15 (18.5)	0.155
Presenting symptoms, N (%)			
Sore throat	77 (18.6)	34 (28.1)	0.222
Cough	255 (59.0)	84 (66.7)	0.159
Shortness of breath	153 (35.6)	54 (43.2)	0.156
Fever	289 (66.4)	75 (59.5)	0.144
Headache	91 (22.2)	23 (19.7)	0.065
Nausea or vomiting	67 (16.0)	11 (9.1)	0.204
Diarrhea	128 (30.4)	20 (16.5)	0.323
Myalgia or arthralgia	146 (35.3)	30 (25.4)	0.209
Vital signs			
Temperature, °C	37.6 ± 1.1	37.6 ± 1.1	0.026
Respiration rate, /min	19.0 ± 5.7	21.1 ± 6.9	-0.336
O2 saturation room air, %	95.2 ± 4.7	94.9 ± 5.5	0.064
Systolic BP, mmHg	132.1 ± 19.1	130.0 ± 19.8	0.105
Diastolic BP, mmHg	79.7 ± 14.1	77.5 ± 14.1	0.159
Pulse rate, BPM	87.4 ± 16.9	89.0 ± 14.5	-0.102
Laboratory test results			
eGFR CKD EPI, ml/min/1.73m ²	41 (26, 61)	36 (25, 56)	0.115
Creatinine increase (>25%)	93 (20.7)	30 (23.1)	0.058
Lymphocytes, x1000/μL	0.9 (0.6, 1.4)	0.8 (0.5, 2.1)	-0.189
CRP, mg/L	26 (6, 70)	41 (10, 88)	-0.128

Continuous variables are reported as mean ± SD or median (IQR). Groups were compared using one way ANOVA, Kruskal Wallis test or Chi-square test as appropriate. Obesity is defined as BMI >30 kg/m². *Abbreviations are:* BMI, body mass index; RAAS=Renin-angiotensin-aldosterone system; CNI= Calcineurin inhibitor; °C, degree Celsius; CRP, C-reactive protein; BP, blood pressure; O2, oxygen; eGFR, estimated glomerular filtration rate.

Table S7: Baseline demographic and clinical characteristics of kidney transplant recipients, with graft function outcome data at 3-month follow-up, by hospitalization and intensive care unit (ICU) admission status in ERACODA.

Variable	Not hospitalized (N=143)	Hospitalized, No ICU (N=297)	Hospitalized, ICU (N=47)	p-value
Patient characteristics				
Male sex, %	95 (66.4)	178 (59.9)	29 (61.7)	0.42
Age, year	50.1 (14.1)	55.9 (13.7)	52.9 (10.1)	<0.001
BMI, kg/m ²	25.7 (4.1)	26.9 (4.7)	28.2 (4.0)	0.004
Race				0.10
White or Caucasian, %	119 (84.4)	236 (82.8)	31 (70.4)	
Non-white, %	22 (15.6)	49 (17.2)	13 (29.5)	
Tobacco use				0.74
Current, %	5 (3.5)	16 (5.4)	1 (2.1)	
Prior, %	27 (18.9)	64 (21.5)	9 (19.1)	
Never, %	73 (51.0)	131 (44.1)	25 (52.3)	
Unknown, %	38 (26.6)	86 (29.0)	12 (25.5)	
Clinical frailty scale, AU	2.3 (1.1)	2.8 (1.4)	2.7 (1.3)	0.002
Comorbidities				
Obesity, %	14 (12.3)	58 (22.9)	13 (30.2)	0.02
Hypertension, %	114 (79.7)	254 (85.5)	40 (85.1)	0.29
Diabetes Mellitus, %	35 (24.5)	84 (28.3)	17 (36.2)	0.29
Coronary artery disease, %	12 (8.4)	44 (14.8)	3 (6.4)	0.07
Heart failure, %	4 (2.8)	16 (5.4)	5 (10.6)	0.10
Chronic lung disease, %	7 (4.9)	20 (6.7)	2 (4.3)	0.65
Active malignancy, %	4 (2.8)	12 (4.0)	0	0.33
Autoimmune disease, %	7 (4.9)	15 (5.0)	3 (6.4)	0.92
Number of reported comorbidities	1 (1, 2)	1 (1, 2)	1 (1, 2)	0.10
Primary kidney disease				
Primary Glomerulonephritis, %	38 (27.3)	54 (18.7)	10 (21.7)	0.13
Pyelonephritis, %	4 (2.9)	12 (4.2)	1 (2.2)	0.69
Interstitial nephritis, %	4 (2.9)	14 (4.9)	1 (2.2)	0.49
Hereditary kidney disease, %	21 (15.1)	48 (16.7)	7 (15.2)	0.91
Congenital diseases, %	12 (8.6)	13 (4.5)	0	0.05
Vascular diseases, %	10 (7.2)	25 (8.7)	5 (10.9)	0.72
Sec. glomerular disease, %	5 (3.6)	13 (4.5)	6 (13.0)	0.03
Diabetic kidney disease, %	10 (7.2)	33 (11.5)	6 (13.0)	0.33
Other, %	15 (10.8)	20 (6.9)	3 (6.5)	0.36
Unknown, %	20 (14.4)	56 (19.4)	7 (15.2)	0.40
Time since transplantation				0.04
<1 year, %	8 (5.7)	23 (7.8)	5 (10.6)	
1-5 years, %	65 (46.1)	107 (36.5)	26 (55.3)	
>5 years, %	68 (48.2)	163 (55.6)	16 (34.0)	
Medication use				
Use of RAAS inhibition, %	61 (43.6)	124 (42.0)	22 (46.8)	0.81

Use of immunosuppressive medication				0.42
Triple therapy	85 (60.7)	193 (66.1)	34 (75.6)	
Dual therapy	52 (37.1)	91 (31.2)	10 (22.2)	
Mono therapy	3 (2.1)	8 (2.7)	1(2.2)	
Disease related characteristics				
Presenting symptoms				
Sore throat, %	22 (18.0)	59 (20.8)	12 (29.3)	0.31
Cough, %	77 (59.2)	175 (60.1)	34 (72.3)	0.25
Shortness of breath, %	18 (13.9)	122 (41.9)	32 (69.6)	<0.001
Fever, %	77 (57.9)	198 (67.8)	36 (78.3)	0.02
Headache, %	28 (23.5)	54 (19.2)	13 (30.2)	0.21
Nausea or vomiting, %	7 (5.7)	49 (17.2)	14 (31.1)	<0.001
Diarrhea, %	27 (22.1)	93 (32.3)	13 (29.5)	0.12
Myalgia or arthralgia, %	49 (40.5)	89 (31.4)	16 (39.0)	0.18
Vital signs				
Temperature, °C	37.4 (1.0)	37.6 (1.1)	37.6 (1.2)	0.27
Respiration rate, /min	15.7 (3.8)	19.1 (5.0)	24.9 (8.0)	<0.001
O2 saturation room air, %	97.3 (1.7)	94.9 (5.2)	92.2 (6.6)	<0.001
Systolic BP, mm Hg	133.0 (15.6)	132.1 (20.2)	125.8 (20.3)	0.10
Diastolic BP, mm Hg	80.2 (11.4)	78.8 (14.3)	78.9 (18.1)	0.76
Pulse rate, BPM	82.8 (14.9)	87.4 (15.1)	94.8 (24.8)	0.001
Intubated, N (%)			24 (51.1%)	
Laboratory test results				
eGFR	51 (32, 67)	39 (25, 53)	36 (22, 55)	0.003
Creatinine increase (>25%)	8 (5.6)	79 (26.6)	19 (40.4)	<0.001
Lymphocytes, x1000/ μ L	1.3 (0.8, 2.2)	0.9 (0.6, 1.3)	0.7 (0.5, 1.3)	<0.001
CRP, mg/L	6 (3.1, 29.5)	31 (9, 76)	58 (24, 106)	<0.001

Continuous variables are reported as mean $\pm$ SD or median (IQR). Groups were compared using one way ANOVA, Kruskal Wallis test or Chi-square test as appropriate. Obesity is defined as BMI >30 kg/m². *Abbreviations are:* ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; BMI, body mass index; RAAS=Renin-angiotensin-aldosterone system; CNI= Calcineurin inhibitor; °C, degree Celsius; CRP, C-reactive protein; BP, blood pressure; O2, oxygen; eGFR, estimated glomerular filtration rate

Table S8: Functional outcomes 3 months after presenting with COVID-19.

	Total (N=450)	Not hospitalized (n=140)	Hospitalized, no ICU (N=270)	Hospitalized, ICU (N=40)	p-value
Functional status					
Reached pre-covid-19 functional status, N (%)					<0.001
• Yes	375 (83.3)	123 (87.9)	235 (87.0)	17 (42.5)	
• No	75 (16.7)	17 (12.1)	35 (13.0)	23 (57.5)	
Limiting factor, N (%)					
o Thromboembolic events ^a	3 (4.0)	1 (5.9)	0	2 (8.7)	0.23
o Impaired lung function	17 (22.7)	3 (17.6)	8 (22.9)	6 (26.1)	0.82
o Disturbed mental health status	5 (6.7)	0	0	5 (21.7)	0.002
o Reduced cognition	2 (2.7)	0	2 (5.7)	0	0.31
o Reduced mobility	16 (21.3)	2 (11.8)	1 (2.9)	13 (56.5)	<0.001
o Reduced muscle strength	24 (32.0)	3 (17.6)	6 (17.1)	15 (65.2)	<0.001
o Tiredness	23 (30.7)	3 (17.6)	10 (28.6)	10 (43.5)	0.20
o Others	6 (8.0)	3 (17.6)	3 (8.6)	0	0.12
o Unknown	49 (65.3)	13 (76.5)	25 (71.4)	11 (47.8)	0.10
Additional time needed to reach prior functional status ^b , N (%)					0.13
o 0-3 months	17 (24.6)	7 (41.2)	7 (24.1)	3 (13.0)	
o 3-6 months	19 (27.5)	5 (29.4)	5 (17.2)	9 (39.1)	
o 6-12 months	19 (27.5)	4 (23.5)	7 (24.1)	8 (34.8)	
o >1 year	5 (7.2)	0	3 (10.3)	2 (8.7)	
o Never	9 (13.0)	1 (5.9)	7 (24.1)	1 (4.3)	

^astroke, pulmonary embolism etc.

^b6 missing.

Table S9. Crude and adjusted Odds ratios (ORs) with 95% confidence interval (CI) for the likelihood that functional status and mental health recovered at 3-month follow-up.

Recovery of pre-COVID-19 functional status			Recovery of pre-COVID-19 mental health status		
Variables	Crude	Adjusted	Variables	Crude	Adjusted
Age (per year)	0.98 (0.96 to 1.00)		Age (per year)	0.98 (0.95 to 1.01)	
Sex (male vs female)	1.18 (0.71 to 1.96)		Sex (male vs female)	1.54 (0.69 to 3.47)	
Body mass index, kg/m ²	0.95 (0.89, 1.00)		Body mass index, kg/m ²	0.92 (0.84, 1.00)	
Clinical frailty score, U	0.73 (0.60, 0.89)	0.74 (0.60, 0.92)	Current smoking (yes vs no)	0.21 (0.06, 0.67)	0.19 (0.05, 0.70)
ICU admission (yes vs no)	0.11 (0.05, 0.21)	0.13 (0.06, 0.26)	Chronic lung disease (yes vs no)	0.31 (0.10, 0.99)	0.30 (0.08, 1.09)
Shortness of breath (yes vs no)	0.36 (0.21, 0.61)	0.54 (0.30, 0.97)	ICU admission (yes vs no)	0.14 (0.06, 0.34)	0.15 (0.06, 0.40)
Saturation, %	1.07 (0.02, 1.13)		Shortness of breath (yes vs no)	0.41 (0.17, 0.98)	
			C-reactive protein, mg/L	0.70 (0.51, 0.96)	0.76 (0.56, 1.04)

Abbreviation: ICU=intensive care unit

Table S10: Mental health status outcomes three months after presenting with COVID-19.

	Total (N=450)	Not hospitalized (N=140)	Hospitalized, no ICU (N=270)	Hospitalized, ICU (N=40)	p-value
Mental health status					
Reached pre-covid-19 mental health status, N (%)					<0.001
• Yes	425 (94.4)	134 (95.7)	260 (96.3)	31 (77.5)	
• No	25 (5.6)	6 (4.3)	10 (3.7)	9 (22.5)	
Limiting factor, N (%)					
o Depression	4 (16.0)	2 (33.3)	0	2 (22.2)	0.17
o Anxiety	5 (20.0)	2 (33.3)	0	3 (33.3)	0.12
o Grief	1 (4.0)	0	0	1 (11.1)	0.40
o Posttraumatic stress disorder	3 (12.0)	1 (16.7)	0	2 (22.2)	0.30
o Memory loss	3 (12.0)	0	2 (20.0)	1 (11.1)	0.49
o Delirium	2 (8.0)	0	1 (10.0)	1 (11.1)	0.71
o Sleep disturbances	3 (12.0)	0	0	3 (33.3)	0.05
o Others	2 (8.0)	0	0	2 (22.2)	0.14
o Unknown					
Additional time needed to reach prior mental health status ^a					0.19
o 0-3 months	4 (22.2)	2 (40.0)	2 (40.0)	0	
o 3-6 months	5 (27.8)	1 (20.0)	1 (20.0)	3 (37.5)	
o 6-12 months	6 (33.3)	2 (40.0)	0	4 (50.0)	
o >1 year	-	-	-	-	
o Never	3 (16.7)	0	2 (40.0)	1 (12.5)	

^aSeven missing.